Developer docs
API playgroundTry for free, no card

Search company profiles

Estrella Immunopharma

Full company profile

uuid00022dw

Namestring
Estrella Immunopharma
Legal namestring
Estrella Immunopharma, Inc.
Websiteurl
estrellabio.com
Company typeenum
Public
Founded yearint
2022
Descriptiontext

Estrella Immunopharma is a clinical-stage biopharmaceutical company developing CD19 and CD22-targeted T-cell therapies for the treatment of B-cell malignancies, autoimmune diseases, and solid tumors. Founded in 2022 as a Delaware corporation headquartered in Emeryville, California, the company went public on NASDAQ (tickers ESLA and ESLAW) in October 2023 following a SPAC business combination with TradeUP Acquisition Corp. that provided approximately $23.11 million in cash. Its product candidates are built on the ARTEMIS (Antibody Redirected T Cells with Endogenous Modular Immune Signaling) platform, licensed from parent company Eureka Therapeutics, which uses a modular antibody-T-cell-receptor (AbTCR) architecture designed to mimic natural T-cell receptor signaling.

The lead product candidate, EB103, is a CD19-redirected ARTEMIS T-cell therapy in Phase I/II STARLIGHT-1 clinical trials for relapsed/refractory B-cell Non-Hodgkin's Lymphoma. The company reported a 100% complete response rate in the high-dose cohort of the Phase I trial (n=9 patients) with no treatment-related serious adverse events and no Grade 3 or higher cytokine release syndrome. Additional pipeline assets include EB104 (a dual CD19/CD22-targeted ARTEMIS T-cell therapy for B-cell malignancies), EB201 (an ARTEMIS T-cell candidate for Systemic Lupus Erythematosus), and a Mark-and-Kill combination approach developed in partnership with Imugene Limited using the CF33-CD19t oncolytic virus to address solid tumors.

As a pre-revenue clinical-stage company, Estrella does not currently generate product revenue. The business model relies on periodic equity capital raises — including a $3.35 million private placement in May 2025 and an $8.0 million registered direct offering in January 2026 — to fund clinical development, with future revenue dependent on regulatory approval and commercialization. Investigational therapies are currently distributed exclusively through clinical trial sites: UC Davis Comprehensive Cancer Center (primary site) and Baylor Scott & White Research Institute. Parent company Eureka Therapeutics, founded and led by CEO Dr. Cheng Liu, is also Estrella's primary technology licensor and equity holder, creating a concentrated ownership and technology structure.

Short descriptiontext

Estrella Immunopharma is a clinical-stage biopharmaceutical company developing CD19 and CD22-targeted ARTEMIS T-cell therapies for B-cell non-Hodgkin's lymphoma, autoimmune diseases, and solid tumors. Lead candidate EB103 showed 100% complete response in Phase I high-dose cohort.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersEmeryville, United States
HQ citystring
Emeryville
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
T-cell immunotherapy, cell therapy development, cancer immunotherapy, biopharmaceutical research, CAR-T alternatives
Industry1 code
PRIMARYHLAAABAC
CAR-T & TCR-T Therapies
Healthcare & Life Sciences/Biotechnology & Biologics/Cell Therapy (autologous/allogeneic)
NAICS code1 code
  • Biological Product (except Diagnostic) Manufacturing325414
SIC code2 codes
  • Biological Products, (No Disgnostic Substances)2836
  • Pharmaceutical Preparations2834
Product category
Cell Therapy Biopharmaceuticals
No data
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1T-cell Therapy Development and Commercialization
TypeOne Time License
Description

As a clinical-stage biopharmaceutical company, Estrella does not currently generate revenue. The company is developing CD19 and CD22-targeted ARTEMIS T-cell therapies for treatment of cancers and autoimmune diseases. Lead product EB103 is in Phase I/II clinical trials for relapsed/refractory B-cell Non-Hodgkin's Lymphoma. Revenue will be generated through commercialization of therapeutic products upon regulatory approval.

estrellabio.com
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels2 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Personnel, Operations, Marketing or Sales, Others
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Estrella Immunopharma is a clinical-stage biopharmaceutical company developing next-generation T-cell immunotherapies built on the ARTEMIS platform licensed from Eureka Therapeutics. Its lead candidate EB103 is a CD19-redirected ARTEMIS T-cell therapy in a Phase I/II trial (STARLIGHT-1) for relapsed/refractory B-cell Non-Hodgkin's Lymphoma, with additional candidates EB104 (dual CD19/CD22) and EB201 (autoimmune disease) in preclinical/early development.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 5 values shown
  • 100% Complete Response rate in high-dose cohort at Month 1 in Phase I STARLIGHT-1 trial
+4 more records
Product overview1 text field

Estrella Immunopharma is a clinical-stage biopharmaceutical company developing a portfolio of ARTEMIS T-cell therapies. The company's core products include EB103 (CD19-targeted) as the lead candidate for B-cell Non-Hodgkin's Lymphoma, EB104 (CD19/CD22 dual-targeted) for DLBCL and ALL, and EB201 for autoimmune diseases like Systemic Lupus Erythematosus. The company also employs a proprietary "mark-and-kill" approach combining EB103 with oncolytic viruses for solid tumor applications. All therapies utilize the ARTEMIS (Antibody Redirected T Cells with Endogenous Modular Immune Signaling) technology platform licensed from parent company Eureka Therapeutics.

Product and service4 records
1EB103 (CD19-Redirected ARTEMIS T-Cell Therapy)
CategoryCell therapy (hematologic malignancy)
Description

Lead product candidate, a CD19-targeted ARTEMIS T-cell therapy in Phase I/II clinical development for adult patients with relapsed/refractory B-cell Non-Hodgkin's Lymphoma (NHL), including aggressive subtypes such as DLBCL. EB103 utilizes ARTEMIS technology licensed from Eureka Therapeutics to target the CD19 protein expressed on B-cell leukemia and lymphoma surfaces, and is designed to reduce Cytokine Release Syndrome and neurotoxicity versus conventional CAR-T therapies.

2EB104 (Dual CD19/CD22-Targeted ARTEMIS T-Cell Therapy)
CategoryCell therapy (hematologic malignancy)
Description

ARTEMIS T-cell therapy candidate designed to simultaneously target both CD19 and CD22 proteins expressed on most B-cell malignancies, including diffuse large B-cell lymphoma (DLBCL) and Acute Lymphocytic Leukemia (ALL).

3EB201 (ARTEMIS T-Cell Therapy for Autoimmune Disease)
CategoryCell therapy (autoimmune disease)
Description

ARTEMIS T-cell therapy candidate being developed for autoimmune diseases, specifically Systemic Lupus Erythematosus (SLE), applying the company's modular T-cell platform beyond oncology.

4EB103 + Oncolytic Virus Combination (Mark-and-Kill Approach)
CategoryCombination cell therapy / oncolytic virus (solid tumor)
Description

Investigational combination strategy pairing CD19-Redirected ARTEMIS T-cells (EB103) with an oncolytic virus (CF33-CD19t) that forces solid tumor cells to express CD19 on their surface, enabling ARTEMIS T-cells to target and kill CD19-labeled solid tumors.

Scale indicator7 records

Each record includes

Type, Value, Description, Source

Partnership3 partners
Strategic tierCoreTypeTechnology or Integration
Description

Eureka Therapeutics is Estrella's parent company that developed and owns the ARTEMIS technology. Estrella has a license agreement with Eureka to utilize ARTEMIS technology for CD19 and CD22-targeted T-cell therapies. Dr. Cheng Liu, Estrella's CEO and President, is also the Founder, President, and CEO of Eureka Therapeutics.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Collaboration with Imugene Limited and its product candidate CF33-CD19t, an oncolytic virus, to research the use of EB103 in conjunction with CF33-CD19t to treat solid tumors using a 'mark and kill' strategy. This partnership expands Estrella's pipeline to address solid tumors beyond blood cancers.

Strategic tierMinorTypeImplementation/ SI/ Consulting Partner
Description

Legal counsel to the company for the January 2026 financing transactions.

Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Markets Yescarta and Tecartus, the leading approved CD19 CAR-T therapies for R/R B-cell NHL. Direct competitor to Estrella's lead candidate EB103 in the same indication, with established commercial infrastructure, real-world evidence base, and manufacturing scale.

TypeDirect peer
Description

Markets Kymriah, the first FDA-approved CD19 CAR-T therapy for R/R B-cell NHL and ALL. Competes head-to-head with EB103 in the same patient population with an entrenched franchise and global commercial reach.

3Bristol-Myers Squibb
TypeDirect peer
Description

Markets Breyanzi, a CD19 CAR-T approved for R/R B-cell NHL. Direct competitor to EB103 with established physician relationships and a growing real-world dataset in aggressive B-cell lymphomas.

TypeDirect peer
Description

Clinical-stage company developing allogeneic (off-the-shelf) CAR-T therapies for hematologic cancers including CD19-targeted candidates. Comparable in clinical-stage status and competing in the same R/R B-cell NHL space.

TypeDirect peer
Description

Clinical-stage allogeneic CAR-T developer with CD19 programs for B-cell malignancies. Direct peer in the autologous/allogeneic CD19 CAR-T space with similar clinical-stage profile.

TypeDirect peer
Description

Developing gene-edited allogeneic CAR-T therapies including CD19-targeted candidates for B-cell malignancies. Comparable in modality and clinical-stage development, with significant capital backing.

TypeDirect peer
Description

Clinical-stage CAR-T developer with CD19 and other hematologic targets. Comparable in clinical-stage positioning and competing in the R/R B-cell NHL space with next-generation CAR-T constructs.

TypeDirect peer
Description

Developing gamma-delta T cell therapies for cancer and autoimmune diseases, including CD19-directed candidates. Closely comparable to Estrella's ARTEMIS platform, which also leverages gamma/delta TCR architecture.

TypeDirect peer
Description

Clinical-stage developer of allogeneic NK cell therapies for cancer and autoimmune disease, including CD19-directed candidates. Comparable in targeting autoimmune (SLE) indications via cell therapy, similar to Estrella's EB201 program.

TypeOthers
Description

Estrella's parent company and licensor of the ARTEMIS technology platform. While not a direct commercial competitor, Eureka is the originating developer of Estrella's core technology and shares leadership with Estrella, making it a strategically relevant ecosystem participant.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat3 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature5 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles8 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds3 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Estrella Immunopharma

Cell Therapy Biopharmaceuticalsestrellabio.com

Estrella Immunopharma is a clinical-stage biopharmaceutical company developing CD19 and CD22-targeted ARTEMIS T-cell therapies for B-cell non-Hodgkin's lymphoma, autoimmune diseases, and solid tumors. Lead candidate EB103 showed 100% complete response in Phase I high-dose cohort.

What Estrella Immunopharma does

Estrella Immunopharma is a clinical-stage biopharmaceutical company developing CD19 and CD22-targeted T-cell therapies for the treatment of B-cell malignancies, autoimmune diseases, and solid tumors. Founded in 2022 as a Delaware corporation headquartered in Emeryville, California, the company went public on NASDAQ (tickers ESLA and ESLAW) in October 2023 following a SPAC business combination with TradeUP Acquisition Corp. that provided approximately $23.11 million in cash. Its product candidates are built on the ARTEMIS (Antibody Redirected T Cells with Endogenous Modular Immune Signaling) platform, licensed from parent company Eureka Therapeutics, which uses a modular antibody-T-cell-receptor (AbTCR) architecture designed to mimic natural T-cell receptor signaling.

The lead product candidate, EB103, is a CD19-redirected ARTEMIS T-cell therapy in Phase I/II STARLIGHT-1 clinical trials for relapsed/refractory B-cell Non-Hodgkin's Lymphoma. The company reported a 100% complete response rate in the high-dose cohort of the Phase I trial (n=9 patients) with no treatment-related serious adverse events and no Grade 3 or higher cytokine release syndrome. Additional pipeline assets include EB104 (a dual CD19/CD22-targeted ARTEMIS T-cell therapy for B-cell malignancies), EB201 (an ARTEMIS T-cell candidate for Systemic Lupus Erythematosus), and a Mark-and-Kill combination approach developed in partnership with Imugene Limited using the CF33-CD19t oncolytic virus to address solid tumors.

As a pre-revenue clinical-stage company, Estrella does not currently generate product revenue. The business model relies on periodic equity capital raises — including a $3.35 million private placement in May 2025 and an $8.0 million registered direct offering in January 2026 — to fund clinical development, with future revenue dependent on regulatory approval and commercialization. Investigational therapies are currently distributed exclusively through clinical trial sites: UC Davis Comprehensive Cancer Center (primary site) and Baylor Scott & White Research Institute. Parent company Eureka Therapeutics, founded and led by CEO Dr. Cheng Liu, is also Estrella's primary technology licensor and equity holder, creating a concentrated ownership and technology structure.

Estrella Immunopharma firmographics

Firmographics
Name
Estrella Immunopharma
Legal name
Estrella Immunopharma, Inc.
Website
https://estrellabio.com
Company type
Public
Founded year
2022
Operating status
Operating
Headcount range
11–50 employees
Short description
Estrella Immunopharma is a clinical-stage biopharmaceutical company developing CD19 and CD22-targeted ARTEMIS T-cell therapies for B-cell non-Hodgkin's lymphoma, autoimmune diseases, and solid tumors. Lead candidate EB103 showed 100% complete response in Phase I high-dose cohort.
Ownership category
akta.pro rank

Estrella Immunopharma industry classification

Industry
Product category
Cell Therapy Biopharmaceuticals
NAICS
Biological Product (except Diagnostic) Manufacturing (325414)
SIC
Biological Products, (No Disgnostic Substances) (2836), Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYHLAAABAC
CAR-T & TCR-T Therapies
Healthcare & Life Sciences/Biotechnology & Biologics/Cell Therapy (autologous/allogeneic)

Keywords

  • T-cell immunotherapy
  • Cell therapy development
  • Cancer immunotherapy
  • Biopharmaceutical research
  • CAR-T alternatives

Where Estrella Immunopharma is headquartered

Location

Headquarters

HQ city
Emeryville
HQ country
United States
HQ region
North America

Offices1 record

Markets served

Estrella Immunopharma business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales, Others

Revenue model

  1. T-cell Therapy Development and Commercialization: As a clinical-stage biopharmaceutical company, Estrella does not currently generate revenue. The company is developing CD19 and CD22-targeted ARTEMIS T-cell therapies for treatment of cancers and autoimmune diseases. Lead product EB103 is in Phase I/II clinical trials for relapsed/refractory B-cell Non-Hodgkin's Lymphoma. Revenue will be generated through commercialization of therapeutic products upon regulatory approval.

Go-to-market motion1 record

Distribution channels2 records

Marketing channels5 records

Estrella Immunopharma product offering

Product offering

Core offering

Estrella Immunopharma is a clinical-stage biopharmaceutical company developing next-generation T-cell immunotherapies built on the ARTEMIS platform licensed from Eureka Therapeutics. Its lead candidate EB103 is a CD19-redirected ARTEMIS T-cell therapy in a Phase I/II trial (STARLIGHT-1) for relapsed/refractory B-cell Non-Hodgkin's Lymphoma, with additional candidates EB104 (dual CD19/CD22) and EB201 (autoimmune disease) in preclinical/early development.

Product overview

Estrella Immunopharma is a clinical-stage biopharmaceutical company developing a portfolio of ARTEMIS T-cell therapies. The company's core products include EB103 (CD19-targeted) as the lead candidate for B-cell Non-Hodgkin's Lymphoma, EB104 (CD19/CD22 dual-targeted) for DLBCL and ALL, and EB201 for autoimmune diseases like Systemic Lupus Erythematosus. The company also employs a proprietary "mark-and-kill" approach combining EB103 with oncolytic viruses for solid tumor applications. All therapies utilize the ARTEMIS (Antibody Redirected T Cells with Endogenous Modular Immune Signaling) technology platform licensed from parent company Eureka Therapeutics.

Differentiator

Problem solved

Functional benefit

Products and services

  • EB103 (CD19-Redirected ARTEMIS T-Cell Therapy) Lead product candidate, a CD19-targeted ARTEMIS T-cell therapy in Phase I/II clinical development for adult patients with relapsed/refractory B-cell Non-Hodgkin's Lymphoma (NHL), including aggressive subtypes such as DLBCL. EB103 utilizes ARTEMIS technology licensed from Eureka Therapeutics to target the CD19 protein expressed on B-cell leukemia and lymphoma surfaces, and is designed to reduce Cytokine Release Syndrome and neurotoxicity versus conventional CAR-T therapies.
  • EB104 (Dual CD19/CD22-Targeted ARTEMIS T-Cell Therapy) ARTEMIS T-cell therapy candidate designed to simultaneously target both CD19 and CD22 proteins expressed on most B-cell malignancies, including diffuse large B-cell lymphoma (DLBCL) and Acute Lymphocytic Leukemia (ALL).
  • EB201 (ARTEMIS T-Cell Therapy for Autoimmune Disease) ARTEMIS T-cell therapy candidate being developed for autoimmune diseases, specifically Systemic Lupus Erythematosus (SLE), applying the company's modular T-cell platform beyond oncology.
  • EB103 + Oncolytic Virus Combination (Mark-and-Kill Approach) Investigational combination strategy pairing CD19-Redirected ARTEMIS T-cells (EB103) with an oncolytic virus (CF33-CD19t) that forces solid tumor cells to express CD19 on their surface, enabling ARTEMIS T-cells to target and kill CD19-labeled solid tumors.

Quantifiable outcome

  • 100% Complete Response rate in high-dose cohort at Month 1 in Phase I STARLIGHT-1 trial
  • +4 more outcomes

Companies that use Estrella Immunopharma

Customer profile

Segments4 records

Ideal customer profiles2 records

Estrella Immunopharma technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature5 records

Estrella Immunopharma partnerships and signals

Strategic signal

Partnerships

Three partnerships are on record, tiered core and minor.

  • Eureka Therapeutics, Inc.coreTechnology or IntegrationEureka Therapeutics is Estrella's parent company that developed and owns the ARTEMIS technology. Estrella has a license agreement with Eureka to utilize ARTEMIS technology for CD19 and CD22-targeted T-cell therapies. Dr. Cheng Liu, Estrella's CEO and President, is also the Founder, President, and CEO of Eureka Therapeutics.
  • Imugene LimitedcoreStrategic or Co-development PartnerCollaboration with Imugene Limited and its product candidate CF33-CD19t, an oncolytic virus, to research the use of EB103 in conjunction with CF33-CD19t to treat solid tumors using a 'mark and kill' strategy. This partnership expands Estrella's pipeline to address solid tumors beyond blood cancers.
  • Winston & Strawn LLPminorImplementation/ SI/ Consulting PartnerLegal counsel to the company for the January 2026 financing transactions.

Scale indicators7 records

Recent moves7 records

Expansion highlights5 records

Estrella Immunopharma competitors and assessment

Company assessment

Direct peers

  • Gilead Sciences (Kite Pharma): Markets Yescarta and Tecartus, the leading approved CD19 CAR-T therapies for R/R B-cell NHL. Direct competitor to Estrella's lead candidate EB103 in the same indication, with established commercial infrastructure, real-world evidence base, and manufacturing scale.
  • Novartis: Markets Kymriah, the first FDA-approved CD19 CAR-T therapy for R/R B-cell NHL and ALL. Competes head-to-head with EB103 in the same patient population with an entrenched franchise and global commercial reach.
  • Bristol-Myers Squibb: Markets Breyanzi, a CD19 CAR-T approved for R/R B-cell NHL. Direct competitor to EB103 with established physician relationships and a growing real-world dataset in aggressive B-cell lymphomas.
  • Allogene Therapeutics: Clinical-stage company developing allogeneic (off-the-shelf) CAR-T therapies for hematologic cancers including CD19-targeted candidates. Comparable in clinical-stage status and competing in the same R/R B-cell NHL space.
  • Caribou Biosciences: Clinical-stage allogeneic CAR-T developer with CD19 programs for B-cell malignancies. Direct peer in the autologous/allogeneic CD19 CAR-T space with similar clinical-stage profile.
  • CRISPR Therapeutics: Developing gene-edited allogeneic CAR-T therapies including CD19-targeted candidates for B-cell malignancies. Comparable in modality and clinical-stage development, with significant capital backing.
  • Autolus Therapeutics: Clinical-stage CAR-T developer with CD19 and other hematologic targets. Comparable in clinical-stage positioning and competing in the R/R B-cell NHL space with next-generation CAR-T constructs.
  • Adicet Bio: Developing gamma-delta T cell therapies for cancer and autoimmune diseases, including CD19-directed candidates. Closely comparable to Estrella's ARTEMIS platform, which also leverages gamma/delta TCR architecture.
  • Nkarta: Clinical-stage developer of allogeneic NK cell therapies for cancer and autoimmune disease, including CD19-directed candidates. Comparable in targeting autoimmune (SLE) indications via cell therapy, similar to Estrella's EB201 program.

Others

  • Eureka Therapeutics: Estrella's parent company and licensor of the ARTEMIS technology platform. While not a direct commercial competitor, Eureka is the originating developer of Estrella's core technology and shares leadership with Estrella, making it a strategically relevant ecosystem participant.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat3 records

Key risks6 records

Key highlights6 records

Customer concentration

Estrella Immunopharma financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Estrella Immunopharma leadership team

Management profile

Number of profiles

Profiles8 records

Estrella Immunopharma funding detail

Funding detail

Funding overview

Funding rounds3 records

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Estrella Immunopharma M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Estrella Immunopharma

What does Estrella Immunopharma do?

Estrella Immunopharma is a clinical-stage biopharmaceutical company developing next-generation T-cell immunotherapies built on the ARTEMIS platform licensed from Eureka Therapeutics. Its lead candidate EB103 is a CD19-redirected ARTEMIS T-cell therapy in a Phase I/II trial (STARLIGHT-1) for relapsed/refractory B-cell Non-Hodgkin's Lymphoma, with additional candidates EB104 (dual CD19/CD22) and EB201 (autoimmune disease) in preclinical/early development.

Is Estrella Immunopharma a public or private company?

Estrella Immunopharma is a public company. It is classified as public and is currently operating.

When was Estrella Immunopharma founded?

Estrella Immunopharma was founded in 2022. It employs 11 to 50 people.

Where is Estrella Immunopharma based?

Estrella Immunopharma is headquartered in Emeryville, United States, in the North America region.

How does Estrella Immunopharma make money?

One revenue line is on record: T-cell Therapy Development and Commercialization.

Who are Estrella Immunopharma's main competitors?

Direct peers on record are Gilead Sciences (Kite Pharma), Novartis, Bristol-Myers Squibb, Allogene Therapeutics, Caribou Biosciences, CRISPR Therapeutics, Autolus Therapeutics, Adicet Bio and Nkarta. Eureka Therapeutics is listed as an others.

Does Estrella Immunopharma have an API?

No public API is recorded for Estrella Immunopharma.

What industry is Estrella Immunopharma in?

Estrella Immunopharma's product category is Cell Therapy Biopharmaceuticals. Its primary akta.pro industry code is HLAAABAC, CAR-T & TCR-T Therapies. Its NAICS code is 325414 and its SIC code is 2836.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Quiver QuantitativeESTRELLA IMMUNOPHARMA ($ESLA) Releases Q3 2026 Earnings | ESLA Stock NewsESTRELLA IMMUNOPHARMA reported Q3 2026 earnings of -$0.17 per share, missing estimates of -$0.08 by $0.09, with revenue of $0. The stock fell 13.11% after market open. Hedge fund activity showed 4 institutions added shares while 10 reduced positions.MarketScreenerEstrella Immunopharma, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2026Estrella Immunopharma reported a Q3 net loss of $7.38 million, up from $4.8 million a year ago, and a nine-month net loss of $11.98 million, down from $12.45 million. Basic and diluted loss per share from continuing operations were $0.17 and $0.28, respectively, compared to $0.13 and $0.34 a year ago.Investing.comEstrella highlights preclinical data for ARTEMIS therapy at ASHEstrella Immunopharma announced preclinical data for its ARTEMIS antibody-TCR T-cell therapy, showing approximately 10,000-fold reductions in leukemia burden across AML and B-ALL models. The therapy demonstrated complete regression of extramedullary AML lesions and disease-free survival beyond 100 days in mice, with faster and deeper responses than conventional CAR-T cells.Business Wire BlogEstrella Immunopharma Highlights ARTEMIS® T-Cell Therapy Data Selected for ASH 2026, Demonstrating Deep and Durable Leukemia Responses and Superior Extramedullary Disease Clearance Versus ConventionalEstrella Immunopharma highlighted preclinical ARTEMIS T-cell therapy data for ASH 2026, showing ~10,000-fold reductions in leukemia burden and complete regression of extramedullary AML lesions. The therapy outperformed conventional CAR-T, with treated mice disease-free beyond day 100. Findings support further investigation of the ARTEMIS platform, including Estrella's clinical-stage EB103 program.Stock TitanEstrella ARTEMIS preclinical data: ~10,000-fold leukemia dropEstrella Immunopharma highlighted preclinical ARTEMIS T-cell therapy data at ASH 2026, showing ~10,000-fold reductions in leukemia burden in AML and B-ALL models. The therapy achieved complete regression of extramedullary AML lesions and disease-free survival beyond 100 days, outperforming conventional CAR-T. Findings support further investigation of the ARTEMIS platform, including Estrella's clinical-stage EB103 program.AdvfnEstrella Immunopharma Highlights ARTEMIS® T-Cell Therapy Data Selected for ASH 2026, Demonstrating Deep and Durable Leukemia Responses and Superior Extramedullary Disease Clearance Versus Conventional CAR-T in Preclinical ModelsEstrella Immunopharma highlighted preclinical ARTEMIS T-cell therapy data accepted for ASH 2026, showing ~10,000-fold reductions in leukemia burden and complete regression of extramedullary AML lesions. The therapy outperformed conventional CAR-T, with disease-free survival beyond 100 days in mice. Findings support further investigation of the ARTEMIS platform, including Estrella's EB103 program.TradingViewEstrella Immunopharma names Cynthia Pussinen CEO; Cheng Liu becomes CSOEstrella Immunopharma appointed Cynthia Pussinen CEO, chairperson, and director, while Cheng Liu became chief scientific officer, effective October 25, 2026. Pussinen's base salary starts at $250,000 and rises to $525,000 at funding thresholds, with a 60% target cash bonus for 2026. Liu's agreement was amended to match Pussinen's terms.BenzingaEstrella Immunopharma Shares Rise 17.91% After Hours - Estrella Immunopharma (NASDAQ:ESLA)Estrella Immunopharma shares rose 17.91% after hours to $0.65, following a 37.50% gain in regular trading. The move followed an update on its EB103 trial, where a single patient tolerated dual-dose infusions with no serious adverse events. The company plans to use expansion data to shape its pivotal trial strategy.The future of tradingEstrella Immunopharma Treats First Patient With Two EB103 Doses in STARLIGHT-1 Expansion PhaseEstrella Immunopharma reported encouraging initial tolerability in the first patient receiving two EB103 infusions in STARLIGHT-1's dose-expansion phase for relapsed/refractory B-cell non-Hodgkin's lymphoma. The patient received infusions three weeks apart with no treatment-related serious adverse events during the first month. Expansion-cohort data will inform the pivotal trial strategy, with additional safety and efficacy results planned for future reporting.TradingViewEstrella Immunopharma, Inc. (ESLA) Reports Early Tolerability of Two EB103 DosesEstrella Immunopharma reported that the first patient receiving two 5 × 10^6 EB103 T cells/kg infusions three weeks apart in STARLIGHT-1's expansion phase had no treatment-related SAEs in the first month. Earlier high-dose escalation showed 100% CR at Month 1 in evaluable patients, and no SAEs occurred in 9 prior patients.